Klabax

Clarithromycin, the active ingredient in Klabax, is a macrolide antibiotic presented as an oral dosage form for systemic use. It treats a range of bacterial infections, including pneumonia, sinusitis, otitis media, skin infections and is used in combination regimens for Helicobacter pylori eradication.

GNH USA supplies Klabax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clarithromycin is a macrolide antibiotic that targets susceptible bacterial pathogens in several infection categories. - Community‑acquired pneumonia: effective in treating bacterial pneumonia caused by susceptible organisms. - Acute bacterial sinusitis: reduces symptoms and bacterial load in sinus inflammation. - Acute otitis media: clears middle‑ear infections caused by typical pathogens. - Skin and soft‑tissue infections: resolves cellulitis, impetigo and related bacterial skin conditions. - Helicobacter pylori eradication (in combination therapy): contributes to bacterial clearance when used with other agents.

Clarithromycin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: frequent loose stools. - Abdominal pain: cramping or discomfort. - Taste disturbance: altered or metallic taste. - Headache: mild to moderate pain. - Vomiting: occasional episodes.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - QT interval prolongation: may lead to cardiac arrhythmias. - Clostridioides difficile‑associated diarrhea: severe colitis. - Hepatic enzyme elevation: potential liver injury. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: life‑threatening skin reactions. - Severe neutropenia: marked reduction in white blood cells.

Before prescribing clarithromycin, clinicians should consider several safety factors. - Pregnancy: Category B; use only when the potential benefit justifies the potential risk to the fetus. - Breastfeeding: excreted in milk; weigh infant benefits against possible adverse effects. - Hepatic impairment: dose adjustment may be required; monitor liver function tests. - Cardiac risk: avoid in patients with known QT prolongation or electrolyte disturbances. - Drug‑resistant organisms: verify susceptibility before use. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Clarithromycin interacts with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Erythromycin and other macrolides: additive risk of QT prolongation. - Cisapride: may cause serious cardiac arrhythmias. - Theophylline: clarithromycin can increase serum theophylline concentrations. - Antacids containing aluminum or magnesium: reduce clarithromycin absorption.

Moderate Interactions (Monitor Closely): - Warfarin: potential enhancement of anticoagulant effect; monitor INR. - Statins (e.g., simvastatin): increased risk of myopathy. - Carbamazepine: may lower clarithromycin plasma levels, reducing efficacy.